News

Emerging Biotech Companies at Cantech 2017

8 years ago Jan 17, 2017

ProMIS Neurosciences, RepliCel Life Sciences, and Critical Outcome Technologies take the stageView Article by Pia...

RepliCel – Using Cells for Healing

8 years ago Jan 15, 2017

View featured company Article on Advisor Access click here

RepliCel CEO Lee Buckler talks to Cantech Letter

8 years ago Jan 10, 2017

View Article by Nick Waddell on Cantech Letter click here (1/11/2017)...

2017 EBD Biotech Showcase

8 years ago Jan 08, 2017

RepliCel presented and conducted one-on-one partnering meetings.

RepliCel CEO Provides 2017 Forecast

8 years ago Jan 04, 2017

After a year of restructuring, RepliCel poised for multiple clinical trial data announcements and completion...

The Jake Brown Show

8 years ago Dec 06, 2016

Episode 10: SNY’s Taylor Rooks, Stylist Megan Wilson, Replicel’s Lee Buckler Released Dec 07, 2016...

Total Tutor with Neil Haley

8 years ago Nov 27, 2016

The Total Tutor Neil Haley will interview Lee Buckler of Replicel. Click here to view:...

RepliCel Life Sciences Announces Closing of Private Placement

8 years ago Oct 30, 2016

Completed Financing Positions RepliCel Through Upcoming Milestones VANCOUVER, BC – October 31, 2016 – RepliCel...

RepliCel Life Sciences Amends Terms of Private Placement

8 years ago Oct 06, 2016

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

RepliCel Announces Debt Settlement

8 years ago Sep 26, 2016

VANCOUVER, BC – September 27, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP)...

RepliCel Provides Update on Shiseido License and Co-Development for RCH-01

8 years ago Sep 25, 2016

VANCOUVER, BC – September 26 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP)...

RepliCel Life Sciences Announces Non-Brokered Private Placement

8 years ago Sep 13, 2016

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

Replicel Life Sciences Share Consolidation Approved

8 years ago Aug 08, 2016

Capital Structure Restructuring Expected to Lead to Financing and Milestones VANCOUVER, BC – August 9,...

Replicel Life Sciences Continues Restructuring with Share Structure Consolidation

8 years ago Jul 21, 2016

VANCOUVER, BC – July 22, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...

RepliCel’s Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan

8 years ago Jul 20, 2016

VANCOUVER, BC – July 21, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)...

Replicel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price

9 years ago Apr 28, 2016

VANCOUVER, BC – April 29, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...

RepliCel Life Sciences conducts formal consultation review with Japan’s PMDA and receives unprecedented review fee reduction

9 years ago Apr 24, 2016

Japan’s Pharmaceuticals and Medical Devices Agency reviews RepliCel’s pre-clinical, quality, and manufacturing data for its...

RepliCel Life Sciences Finishes Enrolment for its Tendon Repair and Skin Rejuvenation Clinical Trials

9 years ago Apr 19, 2016

Results from both trials will support commercialization initiatives, partner discussions and continued clinical developmentVANCOUVER, BC...

Replicel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant Expiry Dates

9 years ago Apr 07, 2016

VANCOUVER, BC – April 8, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...

RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement

9 years ago Apr 05, 2016

VANCOUVER, BC – April 6, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...

by Type

by Topic

by month

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.